AN INTERNATIONAL COMPARISON OF REIMBURSEMENT FOR DIEAP FLAP BREAST RECONSTRUCTION
Caroline SZPALSKI, Alex REID, Nicholas SHEPPARD, Colin MORRISON, Philip BLONDEEL Brussels, Belgium introduCtion: The deep inferior epigastric artery perforator (DIEAP) flap is currently considered the gold standard for autologous breast reconstruction. With the current economic climate and health cutbacks, we decided to survey reimbursement for DIEAP flaps performed at the main international centres in order to assess whether they are funded consistently.
Materials and Methods:
Data were collected confidentially from the main international centres by an anonymous questionnaire.
results:
Our results illustrate the wide disparity in international DIEAP flap breast reconstruction reimbursement: a unilateral DIEAP flap performed in New York, USA, attracts V20,759, whereas the same operation in Madrid, Spain, will only be reimbursed for V300. Only 35.7% of the surgeons can set up their own fee. Moreover, 85.7% of the participants estimated that the current fees are insufficient, and most of them feel that we are evolving towards an even lower reimbursement rate. In 55.8% of the countries represented, there is no DIEAP-specific coding; in comparison, 74.4% of the represented countries have a specific coding for transverse rectus abdominis (TRAM) flaps. Finally, despite the fact that DIEAP flaps have become the gold standard for breast reconstruction, they comprise only a small percentage of all the total number of breast reconstruction procedures performed (7e15%), with the only exception being Belgium (40%).
ConClusions: Our results demonstrate that DIEAP flap breast reconstruction is inconsistently funded. Unfortunately though, it appears that the current reimbursement offered by many countries may dissuade institutions and surgeons from offering this procedure. However, substantial evidence exists supporting the costeffectiveness of perforator flaps for breast reconstruction, and, in our opinion, the long-term clinical benefits for our patients are so important that this investment of time and money is absolutely essential.
TWO-STAGE IMPLANT-BASED BREAST RECONSTRUCTION IS SAFER THAN IMMEDIATE ONE-STAGE IMPLANT-BASED BREAST RECONSTRUCTION AUGMENTED WITH AN ACELLULAR DERMAL MATRIX: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL

Rieky DIKMANS, Vera NEGENBORN, Mark-Bram BOUMAN, Margriet MULLENDER
Amsterdam, The Netherlands introduCtion:
The evidence justifying the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR) is limited. The aim of this prospective randomized trial was to compare the outcomes of direct IBBR augmented with an ADM (Stratticeª, LifeCell Cooperation) with those of two-stage IBBR. We report on the first results on the safety outcomes of the two procedures.
